Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)
USD 14.17
(-0.14%)
USD 14.17
(-0.14%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -45.07 Million USD | -13.16% |
| 2022 | -39.83 Million USD | 28.85% |
| 2021 | -55.98 Million USD | 54.41% |
| 2020 | -122.81 Million USD | -59.28% |
| 2019 | -77.1 Million USD | -35.87% |
| 2018 | -56.74 Million USD | -74.27% |
| 2017 | -32.56 Million USD | -62.94% |
| 2016 | -19.98 Million USD | -125.73% |
| 2015 | -8.85 Million USD | -234.46% |
| 2014 | -2.64 Million USD | -375.02% |
| 2013 | -557.27 Thousand USD | -67518.6% |
| 2012 | -824.15 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -9.62 Million USD | 4.76% |
| 2024 Q2 | -10.98 Million USD | -14.19% |
| 2023 Q1 | -17.29 Million USD | -60.2% |
| 2023 FY | -45.07 Million USD | -13.16% |
| 2023 Q4 | -10.1 Million USD | -6.49% |
| 2023 Q3 | -9.48 Million USD | -15.86% |
| 2023 Q2 | -8.18 Million USD | 52.66% |
| 2022 Q4 | -10.79 Million USD | -31.97% |
| 2022 Q3 | -8.18 Million USD | 33.7% |
| 2022 Q2 | -12.34 Million USD | -44.88% |
| 2022 Q1 | -8.51 Million USD | 14.81% |
| 2022 FY | -39.83 Million USD | 28.85% |
| 2021 Q1 | -15.41 Million USD | 25.94% |
| 2021 Q2 | -16.7 Million USD | -8.35% |
| 2021 Q3 | -13.87 Million USD | 16.92% |
| 2021 FY | -55.98 Million USD | 54.41% |
| 2021 Q4 | -9.99 Million USD | 27.94% |
| 2020 Q3 | -33.97 Million USD | 10.92% |
| 2020 Q2 | -38.13 Million USD | -27.62% |
| 2020 Q1 | -29.88 Million USD | -9.91% |
| 2020 FY | -122.81 Million USD | -59.28% |
| 2020 Q4 | -20.81 Million USD | 38.74% |
| 2019 Q3 | -25.09 Million USD | -1571.76% |
| 2019 FY | -77.1 Million USD | -35.87% |
| 2019 Q1 | -26.52 Million USD | -50.77% |
| 2019 Q4 | -27.19 Million USD | -8.34% |
| 2019 Q2 | 1.7 Million USD | 106.43% |
| 2018 Q2 | -12.39 Million USD | -4.46% |
| 2018 Q1 | -11.86 Million USD | -9.23% |
| 2018 FY | -56.74 Million USD | -74.27% |
| 2018 Q4 | -17.59 Million USD | -18.08% |
| 2018 Q3 | -14.89 Million USD | -20.21% |
| 2017 Q3 | -6.95 Million USD | 4.59% |
| 2017 FY | -32.56 Million USD | -62.94% |
| 2017 Q2 | -7.29 Million USD | 2.16% |
| 2017 Q4 | -10.86 Million USD | -56.13% |
| 2017 Q1 | -7.45 Million USD | 1.58% |
| 2016 Q3 | -5.33 Million USD | -27.25% |
| 2016 FY | -19.98 Million USD | -125.73% |
| 2016 Q4 | -7.57 Million USD | -41.97% |
| 2016 Q2 | -4.19 Million USD | -45.18% |
| 2016 Q1 | -2.88 Million USD | -15.45% |
| 2015 Q4 | -2.5 Million USD | -10.9% |
| 2015 Q2 | -2.56 Million USD | -66.92% |
| 2015 Q1 | -1.53 Million USD | -21.94% |
| 2015 FY | -8.85 Million USD | -234.46% |
| 2015 Q3 | -2.25 Million USD | 12.01% |
| 2014 Q4 | -1.25 Million USD | -53.88% |
| 2014 FY | -2.64 Million USD | -375.02% |
| 2014 Q3 | -818.2 Thousand USD | -76.22% |
| 2014 Q2 | -464.29 Thousand USD | -339.49% |
| 2014 Q1 | -105.64 Thousand USD | 61.76% |
| 2013 Q3 | -45.34 Thousand USD | 76.88% |
| 2013 Q1 | -39.57 USD | 0.0% |
| 2013 Q2 | -196.1 Thousand USD | -495442.42% |
| 2013 Q4 | -276.25 Thousand USD | -509.23% |
| 2013 FY | -557.27 Thousand USD | -67518.6% |
| 2012 FY | -824.15 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 73.356% |
| Dynavax Technologies Corporation | -37.02 Million USD | -21.738% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -755.519% |
| Perrigo Company plc | 151.9 Million USD | 129.676% |
| Illumina, Inc. | -1.06 Billion USD | 95.783% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 100.657% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 90.212% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.68% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 102.28% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 59.248% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 101.114% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -0.919% |
| Waters Corporation | 817.67 Million USD | 105.513% |
| Biogen Inc. | 1.29 Billion USD | 103.476% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 83.549% |
| Evolus, Inc. | -49.23 Million USD | 8.441% |
| Adicet Bio, Inc. | -152.03 Million USD | 70.351% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 62.898% |
| bluebird bio, Inc. | -244.26 Million USD | 81.546% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 71.023% |
| FibroGen, Inc. | -281.81 Million USD | 84.005% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 103.339% |
| Homology Medicines, Inc. | -48.25 Million USD | 6.585% |
| Geron Corporation | -193.94 Million USD | 76.758% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 84.025% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 38.665% |
| Myriad Genetics, Inc. | -123.7 Million USD | 63.559% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 55.292% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 91.252% |
| Zoetis Inc. | 3.06 Billion USD | 101.469% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 6.479% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 104.146% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 123.183% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 101.046% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -15.131% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 87.257% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 83.668% |
| Verastem, Inc. | -92.08 Million USD | 51.048% |
| Nektar Therapeutics | -137.42 Million USD | 67.199% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 80.555% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 53.699% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 83.169% |
| OPKO Health, Inc. | -157.02 Million USD | 71.292% |
| Exelixis, Inc. | 170.88 Million USD | 126.379% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 117.966% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 142.018% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 19.153% |
| uniQure N.V. | -282.87 Million USD | 84.064% |
| Imunon, Inc. | -21.03 Million USD | -114.343% |
| Blueprint Medicines Corporation | -486.27 Million USD | 90.73% |
| Insmed Incorporated | -709.62 Million USD | 93.648% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 113.353% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 88.486% |
| TG Therapeutics, Inc. | 20.63 Million USD | 318.472% |
| Incyte Corporation | 620.52 Million USD | 107.264% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 93.794% |